Raynaud's phenomenon and plasma endothelin: Correlations with capillaroscopic patterns in systemic sclerosis

Journal of Rheumatology

Volumn 36, Issue 6, 2009, Pages 1235-1239

  Sulli, Alberto ^a   Soldano, Stefano ^a   Pizzorni, Carmen ^a   Montagna, Paola ^a   Secchi, Maria Elena ^a   Villaggio, Barbara ^a   Seriolo, Bruno ^a   Brizzolara, Renata ^a   Cutolo, Maurizio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Capillaroscopy; Endothelin 1; Microangiopathy; Raynaud's phenomenon; Systemic sclerosis

Indexed keywords

ENDOTHELIN 1;

ADULT; AGED; ARTICLE; BLOOD VESSEL INJURY; CAPILLAROSCOPY; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; CAPILLARIES; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN; YOUNG ADULT;

EID: 67149146809     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081030     Document Type: Article

References (37)

1. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 2003;48:3023-3030 (Pubitemid 37409311)
2. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-1576 (Pubitemid 32660630)
3. LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485-488
4. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002;51:3517-3523 (Pubitemid 35403459)
5. Kowal-Bielecka O. Targeting vascular disease in systemic sclerosis. Endocr Metab Immune Disord Drug Targets 2006;6:401-407 (Pubitemid 44941928)
6. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998;31 Suppl:S545-7. (Pubitemid 128710007)
7. Tabata H, Yamakage A, Yamazaki S. Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. Int J Dermatol 1997;36:272-275 (Pubitemid 27242619)
8. Kawaguchi Y, Suzuki K, Hara M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994;53:506-510 (Pubitemid 24256979)
9. Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:417-425 (Pubitemid 32202907)
10. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998;31 Suppl:S360-3.
11. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005;24:111-116 (Pubitemid 40552961)
12. Silveri F, De Angelis R, Poggi A, et al. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon and RP secondary to systemic sclerosis. Scand J Rheumatol 2001;30:290-296 (Pubitemid 32980342)
13. Morelli S, Ferri C, Polettini E, et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995;99:55-60.
14. Maeda M, Kachi H, Takagi H, Kitajima Y. Is there circadian variation of plasma endothelin (ET-1) in patients with systemic scleroderma (SSc)? J Dermatol Sci 1997;16:38-44. (Pubitemid 28004772)
15. Mukerjee D, Yap LB, Ong V, et al. The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension. Ann Rheum Dis 2004;63:1627-1631 (Pubitemid 39573693)
16. Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC. Microvascular abnormalities as possible predictors of disease subset in Raynaud's phenomenon and early connective tissue disease. Clin Exp Rheumatol 1983;1:195-205. (Pubitemid 14210276)
17. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27:155-160 (Pubitemid 30058643)
18. Cutolo M, Pizzorni C, Sulli A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al. Arthritis Rheum 2007;56:2102-2103
19. Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990;16:75-91. (Pubitemid 20116146)
20. Kabasakal Y, Elvins DM, Ring EFJ, McHugh NJ. Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. Ann Rheum Dis 1996;55:507-512 (Pubitemid 26249033)
21. Grassi W, Medico PD, Izzo F, Cervini C. Microvascular involvement in systemic sclerosis: capillaroscopic findings. Semin Arthritis Rheum 2001;30:397-402. (Pubitemid 32565325)
22. Cutolo M, Pizzorni C, Tuccio M, et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology 2004;43:719-726 (Pubitemid 38807428)
23. Blockmans D, Beyens G, Verhaeghe R. Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue disease. Clin Rheumatol 1996;15:148-153 (Pubitemid 26124297)
24. Maricq HR, Le Roy EC, D'Angelo WA, et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980;23:183-189 (Pubitemid 10164324)
25. Cutolo M, Pizzorni C, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol 2005;19:437-452
26. LeRoy EC, Black CM, Fleischmajer R, et al. Scleroderma (systemic sclerosis); classification, subsets and pathogenesis. J Rheumatol 1988;15:202-205 (Pubitemid 18073738)
27. Andrade LEC, Gabriel A Jr, Assad RL, Ferrari AJL, Atra E. Panoramic nailfold capillaroscopy: a new reading method and normal range. Semin Arthritis Rheum 1990;20:21-31. (Pubitemid 20256970)
28. Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885-887 (Pubitemid 351829394)
29. Schmidt J, Launay D, Soudan B, et al. Assessment of plasma endothelin level measurement in systemic sclerosis. Rev Med Interne 2007;28:371-376 (Pubitemid 46735998)
30. Yamane K, Miyauchi T, Suzuki N, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992;19:1566-1571
31. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-983
32. Kirchengast M, Luz M. Endothelin receptor antagonists: clinical realities and future directions. J Cardiovasc Pharmacol 2005;45:182-191 (Pubitemid 40170682)
33. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991;88:1054-1057
34. Peterlana D, Puccetti A, Caramaschi P, et al. Endothelin-1 serum levels correlate with MCP-1 but not with homocysteine plasma concentration in patients with systemic sclerosis. Scand J Rheumatol 2006;35:133-137
35. Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-1844
36. Soldano S, Montagna P, Villaggio B, et al. Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts. Ann Rheum Dis 2009;68:599-602.
37. Filaci G, Cutolo M, Scudeletti M, et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology 1999;38:992-996 (Pubitemid 29505082)